Watch the discussion with Nigel Theobald, CEO of N4 Pharma, as he delves into the Company's recent Collaboration Agreement with SRI International Inc here.
Investors are invited to submit additional questions via the link above, and our management team will endeavour to respond as soon as we can.
Share your feedback
Questions (0)
Your question will be sent privately to Thalia Therapeutics. The company may choose to make this question public.
Start the conversation
Ask Thalia Therapeutics a question about this announcement.
Discover
